Bank of Nova Scotia
CBAY

Bank of Nova Scotia’s Cymabay Therapeutics CBAY Stock Holding History

Bank of Nova Scotia’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,554
Closed -$118K – 1188
2023
Q1 		$118K Buy
+13,554
New +$109K ﹤0.01% 1107
2022
Q4 		– Sell
-14,286
Closed -$50K – 1268
2022
Q3 		$50K Sell
14,286
-1,410
-9% -$5.07K ﹤0.01% 1137
2022
Q2 		$46K Sell
15,696
-932
-6% -$2.23K ﹤0.01% 1148
2022
Q1 		$52K Buy
16,628
+2,037
+14% +$6.41K ﹤0.01% 1178
2021
Q4 		$55K Buy
+14,591
New +$55.4K ﹤0.01% 1192

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Bank of Nova Scotia's CBAY Position: Q2 2023 in Review

Bank of Nova Scotia sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 13,554 shares — an estimated $118K sold.

Bank of Nova Scotia first reported a position in CBAY in Q4 2021 and held it in 5 quarters. The position peaked at $118K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • Bank of Nova Scotia reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bank of Nova Scotia sold 13,554 Cymabay Therapeutics shares in Q2 2023, an estimated $118K.
  • Bank of Nova Scotia first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 5 quarters.
  • Bank of Nova Scotia's Cymabay Therapeutics position peaked at $118K in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on Bank of Nova Scotia's 13F filing for Q2 2023, filed 3 Aug 2023.